It utilizes a highly scalable method of production and is currently positioned to deliver up to 150 million influenza vaccine doses to support an influenza pandemic response within six months of a pandemic declaration.
The doses combine bulk stockpiles of two key ingredients: an 'antigen' targeted at the H5 portion of the H5N1 virus with an 'adjuvant' designed to boost the immune response triggered by the vaccine.
While manufacturing of these new bird flu doses is set to be completed by 'later this summer,' the vaccines may not be immediately ready for use due to regulatory approval requirements.
While CDC's current risk assessment to the general public is low, the FDA will use regulatory pathways to approve the new H5N1 vaccine if deemed necessary for prevention.
[
Collection
]
[
|
...
]